Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

OKYO Pharma (OKYO) announces that its lead asset, OK-101, has been officially assigned the United States Adopted Name, USAN, “urcosimod”. Gary Jacob, Ph.D., Chief Executive Officer of Okyo Pha ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

MILAN, Feb. 12, 2025 /PRNewswire/ -- DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new ...

- Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...

– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE ...

The yearslong bankruptcy case could be coming to a close. Purdue Pharma’s owners in the Sackler family have agreed to a new $6.5 billion settlement to lawsuits over their role in the U.S. opioid ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

This is the second successful treatment in a donkey, demonstrating the potential of Innocan's Liposomal CBD injection for human and veterinary use HERZLIYA, Israel and CALGARY, AB, Feb. 10, 2025 ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.

Aurora Pharmaceutical logo "Our sales team is the backbone of our customer relationships, and this expansion reflects both our business growth and our dedication to providing best-in-class service to ...